Results 171 to 180 of about 2,092 (196)

Clinical Efficacy of Cerebrolysin and Cerebrolysin plus Nootropics in the Treatment of Patients with Acute Ischemic Stroke in Vietnam

CNS & Neurological Disorders - Drug Targets, 2022
Aims:To investigate the efficacy and safety of Cerebrolysin and Cerebrolysin plus nootropics in the routine treatment of patients with acute ischemic stroke (AIS).Background:Acute ischemic stroke (AIS) is a leading cause of disability with unmet treatment needs lacking effective drug therapy.
Luc Tran, X. Anton Alvarez, Hoang-Anh Le, Dat-Anh Nguyen, Thinh Le, Ngoc Nguyen, Thang Nguyen, Tai Nguyen, Tan Vo, Tuan Tran, Chinh Duong, Huyen Nguyen, Sam Nguyen, Hien Nguyen, Thanh Le, Minh Nguyen, Thang Nguyen   +16 more
openaire   +2 more sources

Evaluation of the antitumor potential of cerebrolysin

Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2016
To investigate the effect of cerebrolysin on the growth and metastasis of malignant tumors in mice (a model of lung carcinoma Lewis).The study was performed on 60 male mice, hybrids F1 (the age of 2-2.5 months, body weight 19-22g.). Transplantable epidermoid Lewis lung carcinoma (LLC) was used as a standard experimental model to evaluate the properties
O A, Gromova, A V, Pronin, I Yu, Torshin, A G, Kalacheva, M V, Filimonova, V I, Demidov, I V, Gogoleva, T R, Grishina   +7 more
openaire   +2 more sources

Pilotforsøg med cerebrolysin til demente patienter

Nordisk Psykiatrisk Tidsskrift, 1981
Forfatterne, Carsten Borup, reservelaege, og Inge-Marie Petersen, 1. reservelage ved Set. hans Hospital i Roskilde, afdeling F, der har geronto-psykiatri som subspeciale og er ledet af overlaege dr. med. Sven Munch-Petersen, har med folgende artikel onsket at praesentere en mulig behandling af begyndende demens tilstande.
Birgitte Brun, Carsen Børup og Inge-Marie Petersen   +1 more
openaire   +1 more source

Preparation and Evaluation of the Pegylated Cerebrolysin

Advanced Materials Research, 2011
Four kinds of brain active peptide (BAP) in Cerebrolysin were effectively modified by mPEG-ALD5000 of single molecule. At pH = 5.0, 25°C, with Cerebrolysin (injection)/mPEG-ALD5000 feed ratio of 5 mL : 1 g, the modification rate reached 72.805% after 30 min.
Hong Wei Wang, Zhong Wu Sun, Rong Hua Zhang   +2 more
openaire   +1 more source

Antioxidant systemic effect of short-term Cerebrolysin® administration

1998
Levels of catalase (CAT) and superoxide dismutase (SOD) activity were determinate in serum of intact rats (INT) and those with septohippocampal pathway lesion (SHPL), which received Cerebrolysin (CRB) or saline solution (SAL) for a week. We found that Cerebrolysin induces a decrease on the CAT and SOD levels.
M E, González, L, Francis, O, Castellano   +2 more
openaire   +2 more sources

Efficacy of Cerebrolysin® in Alzheimer’s disease

1994
Background. Alzheimer’s disease (AD) accounts for about half of all cases of senile dementia. Its prevelance increases steeply with age, from less than 1% at 60 to 15% in the 9th decade. The disease causes great suffering to patients and their families, and huge costs to society. Four million patients suffer from AD in the USA alone.
E. Ruether, R. Ritter, M. Apecechea, S. Freitag, M. Windisch   +4 more
openaire   +1 more source

Cerebrolysin for acute ischaemic stroke

2015
BACKGROUND: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian and post-Soviet countries. OBJECTIVES: To assess the benefits and risks of
Ziganshina L., Abakumova T.
openaire   +2 more sources

REMOVED: Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease

2019
Parkinson's disease (PD) is affecting >10 million people worldwide for which no suitable cure has been developed so far. Roughly, about two people per thousand populations are affected with PD like symptoms especially over the age of 50. About 1% of the populations above 60 years suffer from PD-like disease.
Asya, Ozkizilcik, Aruna, Sharma, José Vicente, Lafuente, Dafin F, Muresanu, Rudy J, Castellani, Ala, Nozari, Z Ryan, Tian, Herbert, Mössler, Hari Shanker, Sharma   +8 more
openaire   +2 more sources

Immunoactive Properties of Cerebrolysin.

Russian journal of immunology : RJI : official journal of Russian Society of Immunology
In children (aged 3-8 years old) with minimal cerebral dysfunction the immune status was studied before and after cerebrolysin administration in the dosage of 1 ml per 10 kg of child's weight, intramuscularly, within one month. The cerebrolysin administration resulted in an increase in the level of CD19(+) cells with a simultaneous normalization of ...
Nataliya Yu., Sotnikova, Olga A., Gromova, Elena A., Novikova, Eugeny M., Burtsev   +3 more
openaire   +1 more source

Cerebrolysin for acute ischaemic stroke

2016
© 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.Background: Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, Eastern Europe, China, and
Ziganshina L., Abakumova T., Vernay L.
openaire   +4 more sources